|
Daniel L. Vasella, M.D. is Chairman of the Board and Chief Executive Officer of Novartis AG, one of the world’s leading pharmaceutical companies. The company currently operates in five principal industry sectors: Pharmaceuticals, Generics, Consumer Health, CIBA Vision and Animal Health. Novartis was created via the merger of Sandoz Ltd. and Ciba-Geigy Ltd. in 1996. Before the merger, Dan was CEO of Sandoz Pharma Ltd., the pharmaceuticals division of Sandoz. In this capacity, he was responsible for managing all activities of the pharmaceuticals division of the Sandoz Group worldwide. Before joining Sandoz in 1988, Dan held a number of medical positions in Switzerland. Dan is a member of the board of directors of Credit Suisse Group, the Supervisory Board of Siemens AG and the International Board of Governors of the Peres Center of Peace. He is also Vice-Chairman of the International Business Leaders Advisory Council for the Mayor of Shanghai, a member of the Board of Directors of Associates of Harvard Business School, and a member of the boards of INSEAD and IMD. | 